secwatch.observer — SEC 8-K summary
======================================

Issuer:     Neurogene Inc. (NGNE)
CIK:        0001404644
Form:       8-K
Filed at:   2023-12-19T23:59:59+00:00
Accession:  0001193125-23-298152
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.85
Item codes: 5.07, 1.01, 2.01, 9.01, 3.03, 5.01, 5.02, 5.03, 5.05, 5.08, 7.01
LLM model:  deepseek-v4-flash:cloud@v2

Neoleukin completes reverse merger with Neurogene; raises ~$95M PIPE; interim CEO/CFO depart
--------------------------------------------------------------------------------

- Merger closed Dec 18, 2023: Neoleukin renamed Neurogene Inc.; all Neurogene stock converted at 0.0756:1 exchange ratio.
- Pre-closing financing raised ~$95M from 36.9M shares and 24.0M pre-funded warrants. Post-merger shares outstanding: ~16.9M (assuming full exercise).
- Pre-merger Neoleukin stockholders received one CVR per share for potential proceeds from legacy asset sales and lease savings.
- Donna Cochener (Interim CEO/GC) and Sean Smith (Interim CFO) terminated at closing; entered separation agreements with severance.
- Neurogene dosed first two female pediatric Rett syndrome patients in NGN-401 Phase 1/2 trial; no treatment-emergent serious adverse events reported.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1404644/000119312523298152/0001193125-23-298152-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1404644/000119312523298152/d648703d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-298152

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer